Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mochida Pharmaceutical Co., Ltd. ( (JP:4534) ) has provided an announcement.
Mochida Pharmaceutical said an independent auditor has completed its interim review of the consolidated financial statements for the nine months ended Dec. 31, 2025, clearing the way for a previously approved secondary offering of common shares. The company confirmed there are no changes to the figures it released on Feb. 6, underscoring stability in the disclosed numbers as it taps equity markets.
For the nine-month period, Mochida reported net sales of ¥87.5 billion, up 8.4% year on year, with operating profit rising 3.9% to ¥7.5 billion and profit attributable to owners of parent increasing 13.2% to ¥6.3 billion. Total assets expanded to ¥182.2 billion and net assets to ¥137.4 billion, suggesting an improving balance sheet as the company prepares for its share offering.
Basic earnings per share climbed to ¥178.91 from ¥158.11 a year earlier, supported by higher ordinary profit and a sharp rise in comprehensive income to ¥9.57 billion. The completion of the audit review without adjustment should bolster investor confidence in these results ahead of the secondary equity issuance, even as the equity-to-asset ratio eased to 75.4% from 81.6% due to balance-sheet expansion.
The most recent analyst rating on (JP:4534) stock is a Hold with a Yen3985.00 price target. To see the full list of analyst forecasts on Mochida Pharmaceutical Co., Ltd. stock, see the JP:4534 Stock Forecast page.
More about Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. is a Japan-based drugmaker listed on the Tokyo Stock Exchange Prime Market, operating under Japanese GAAP and focused on prescription pharmaceuticals and related healthcare products. The company generates consolidated net sales primarily from its pharmaceutical portfolio and maintains a relatively strong equity-to-asset ratio, reflecting a solid financial base within the domestic healthcare sector.
YTD Price Performance: 4.38%
Average Trading Volume: 37,141
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen125.6B
See more insights into 4534 stock on TipRanks’ Stock Analysis page.